Akili launches pre-FDA. Korea OKs Samsung BP app.

Issue 049.

Get E&O weekly. Subscribe

Digital health research from Brian Dolan.

Welcome to E&O.

Last week's newsletter had a 59 percent open rate. Here's what's happening this week:

I've been heads-down on The 4,400-word Hinge Health Report this past week, which is why this newsletter is mostly just a prompt to dig into the report. More background on it after a few links below...

As I predicted in last week's newsletter, Akili Interactive, which has been waiting on FDA authorization for a long time, launched a version of its ADHD digital therapeutic, Endeavor, under FDA's latest non-enforcement guidance. No cost to families who qualify. The company is still pursuing 510(K) too: More here.
Samsung just received authorization from South Korea's medical device regulatory agency to market its SaMD cuffless blood pressure monitoring app: "Once your Galaxy Watch Active2 device has been

Paying Subscribers Only

It's a good one, too.

This digital health research is for paying Exits & Outcomes subscribers only. Subscribe now to read this article, get the weekly newsletter, and receive unrestricted access to past and future research from the Exits & Outcomes archives. Smash the link above or below to subscribe yourself -- or head over to our pricing page to subscribe your team or your whole company!

Akili launches pre-FDA. Korea OKs Samsung BP app.

Welcome to E&O.

Paying Subscribers Only

Full access to E&O's research and newsletters.

New! E&O's free weekly newsletter.